Company Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases.
The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease.
Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich’s ataxia; and GBA1 gene replacement to treat parkinson’s disease and is in preclinical trial.
Further, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 11, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Alfred Sandrock |
Contact Details
Address: 75 Hayden Avenue Lexington, Massachusetts 02421 United States | |
| Phone | 857 259 5340 |
| Website | voyagertherapeutics.com |
Stock Details
| Ticker Symbol | VYGR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001640266 |
| CUSIP Number | 92915B106 |
| ISIN Number | US92915B1061 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Robin Swartz | Chief Business Officer and Chief Operating Officer |
| Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder |
| Dr. Guangping Gao Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Mark A. Kay M.D., Ph.D. | Founder |
| Dr. Phillip D. Zamore Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer |
| Todd Carter Ph.D. | Chief Scientific Officer |
| Michelle Quinn Smith | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 144 | Filing |
| Sep 5, 2024 | 8-K | Current Report |
| Aug 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |